Blood & Plasma Components Market to Grow with a CAGR of 6.54% through 2030

Growing prevalence of blood disorders and rise in number of road accidents to drive the blood & plasma components market in the forecast period, 2026-2030.

According to TechSci Research report, “Blood & Plasma Components Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2030”, the Global Blood & Plasma Components Market was valued at USD 45.27 billion in 2024 and is expected to reach USD 66.21 billion by 2030 with a CAGR of 6.54% during the forecast period. The growing prevalence of trauma and road accidents, rising volume of surgeries, and increase in number of people from chronic conditions including cancer are the primary factors driving the demand for the global blood & plasma components market. Growing technological advancements, increasing investments for research and development activities, several blood donation campaigns undertaken by various blood organizations, and rising awareness associated with the significance of blood donations are expected to influence the market demand. Also, the strategic initiatives such as partnerships and product launches undertaken by the market players are also a key factor for increasing the growth of the blood & plasma components market, globally.

However, the rising risk of developing or transferring an infection, lesser number of blood banks, and high costs of blood plasma treatments may hamper the growth of the global blood & plasma components market.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Blood & Plasma Components Market"

The global Blood & Plasma Components market is segmented into products, application, end user, regional distribution, and company.

Based on Application, solid tumor management is projected to show the fastest growth in the global blood and plasma components market. This is primarily due to the increasing global cancer burden and the rising use of blood transfusions and plasma-derived products in oncology care. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, responsible for nearly 10 million deaths in 2020. Solid tumors such as breast, lung, colorectal, and liver cancers often require chemotherapy, radiation, and surgical interventions, all of which are associated with a high need for supportive blood and plasma therapies. For example, patients undergoing chemotherapy may experience severe anemia and thrombocytopenia, necessitating transfusions of packed red blood cells and platelets. Similarly, plasma components are used to manage clotting abnormalities in cancer patients.

Based on Region, The Asia-Pacific region is emerging as the fastest-growing market for blood and plasma components, driven by rapid population expansion, rising healthcare investments, and increasing awareness about voluntary blood donation. With more than 4.7 billion people, Asia-Pacific accounts for nearly 60% of the global population, creating immense demand for transfusion medicine and plasma-derived therapies. Several countries in the region face a growing burden of chronic diseases such as cancer, thalassemia, hemophilia, and liver disorders, all of which require blood and plasma-based interventions. For instance, the World Health Organization (WHO) has highlighted that India alone needs over 12 million blood units annually, while China has recorded one of the fastest increases in plasma collection over the past decade to support its large patient population. Government initiatives are playing a crucial role in driving growth. China has expanded plasma collection centers and invested in domestic plasma fractionation to reduce dependence on imports. Similarly, India’s National Blood Policy emphasizes strengthening blood banks and ensuring safe transfusion practices across both rural and urban areas. In Japan, an aging population has resulted in a rising need for plasma-derived immunoglobulins and clotting factors, further fueling market expansion.

Major operating companies operating in Global Blood & Plasma Components Market are:

• CSL Limited
• Grifols S.A.
• ADMA Biologics, Inc.
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Kedrion S.p.A
• Emergent BioSolutions Inc.
• Bio Products Laboratory Ltd.
• LFB S.A.
• Versiti, Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“North America region dominates the market and is expected to maintain its dominance in the coming years due to the existence of a high number of donors and rising prevalence of hemophilia. The huge investment in R&D, constantly improving healthcare infrastructure and facilities, favorable government initiatives, and the improvement in patient awareness about plasma derivatives in the region are another key factor. Also, numerous untapped prospects in the region are expected to propel the global blood & plasma components market growth till 2030” said Mr. Karan Chechi, Research Director of TechSci Research, a research based global management consulting firm.

“Blood & Plasma Components Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products), By Application (Hematology, Solid Tumor Management, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of global blood & plasma components market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global blood & plasma components market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com